MedPath

OcuWize Ltd.

🇮🇱Israel
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 2:2
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 4
1 (33.3%)

Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome

Phase 4
Completed
Conditions
Dry Eye Due to Sjögren's Syndrome
Interventions
Drug: LO2A eye drops
First Posted Date
2017-10-24
Last Posted Date
2021-02-25
Lead Sponsor
Ocuwize LTD
Target Recruit Count
60
Registration Number
NCT03319420
Locations
🇮🇱

HaEmek MC, Afula, Israel

🇮🇱

Rambam, Haifa, Israel

🇮🇱

Rabin MC, Petah tikva, Israel

and more 2 locations

To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis

Phase 2
Completed
Conditions
Conjunctivochalasis
Interventions
Drug: LO2A
Drug: Placebo
First Posted Date
2016-06-22
Last Posted Date
2017-10-27
Lead Sponsor
Ocuwize LTD
Target Recruit Count
13
Registration Number
NCT02810119
Locations
🇮🇱

Barzilai MC, Ashkelon, Israel

Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis

Phase 2
Completed
Conditions
Conjunctivochalasis
Interventions
Drug: LO2A
Drug: Saline
First Posted Date
2016-06-17
Last Posted Date
2021-02-25
Lead Sponsor
Ocuwize LTD
Target Recruit Count
62
Registration Number
NCT02804191
Locations
🇮🇱

Rambam, Haifa, Israel

🇮🇱

Hadassah, Jerusalem, Israel

🇮🇱

Ichilov Tel Aviv hospital, Tel Aviv, Israel

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.